Full Text View
Tabular View
No Study Results Posted
Related Studies
Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
This study has been completed.
Study NCT01055847   Information provided by Gilead Sciences

First Received on January 23, 2010.   Last Updated on January 25, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cystic Fibrosis
CF
Lung Infection
Pseudomonas Aeruginosa
Additional conditions recognized in this trial
Fibrosis
Pseudomonas Infections
More general conditions related to this trial
Bacterial Infections
Digestive System Diseases
Genetic Diseases, Inborn
Gram-Negative Bacterial Infections
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Interventions listed in this trial
Aztreonam for Inhalation (AI)
Placebo
Additional drug interventions recognized in this trial
Aztreonam
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Gilead Sciences
Conducted under Salus Pharma, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services